Bruker Corp Dossier
|
SectorHealth Care IndustryMedical Devices Beta (adjusted)1.19 Intrinsic Value $61.82median of 3 methodsbased on filings through 30 Jun 2026 Market Price $61.94Price as of 1 Oct 2026 Near fair valueIntrinsic value is 0% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $9.4B Enterprise Value $11.1B Shares Outstanding 152.2M diluted Moat Rating None Next Earnings Date4 Nov 2026 Last ex-dividend22 Jun 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Bruker's operating recovery is gaining credibility: Q2 2026 organic revenue returned to growth, BSI organic bookings increased 10%, and non-GAAP operating margin expanded to 14.1%. Management maintained FY2026 organic-growth and non-GAAP EPS guidance while expressing confidence in additional margin and EPS growth during 2027. These positives are balanced by soft US academic demand, a large Q2 goodwill impairment, negative first-half free cash flow, substantial debt, and continuing acquisition-integration demands. At the August 31 intraday price of $56.88, the risk-reward supports a Hold pending evidence that bookings convert into sustained organic growth, cash generation, and lower leverage. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$40.00 Mean target$58.75 High · most bullish analyst$70.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $40.0022% US academic weakness persists, bookings fail to convert into revenue, organic growth falls below guidance, margin recovery stalls, and cash generation remains weak while debt and integration obligations constrain flexibility. Base CaseCentral scenario $58.7558% Matches the consensus meanBruker delivers within its FY2026 guidance of 1% to 2% organic revenue growth and $2.10 to $2.15 non-GAAP EPS, with bookings supporting continued but gradual recovery and cost actions preserving margin improvement. Negative cash flow and acquisition execution limit multiple expansion. Bull CaseUpside scenario $70.0020% A stronger academic and biopharma recovery, continued double-digit BSI bookings momentum, semiconductor-metrology demand, BEST order conversion, and successful commercialization of newer diagnostics, spatial-biology, organ-on-chip, and self-driving-laboratory offerings could sustain margin expansion through 2027. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |